Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab.

Patients with lung or mediastinal lymph node metastases only were more likely to achieve a radiologic response compared to patients with other metastatic sites (70% vs 42%; odds ratio 3.2; 95% CI 1.09–9.15; p = 0.033), with borderline significance for CR (20% vs 8%; odds ratio 3.7; 95% CI 1.00–13.83; p = 0.050).

also in 7,017 other papers